Valiant Laboratories Ltd
Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
- Market Cap ₹ 482 Cr.
- Current Price ₹ 111
- High / Low ₹ 227 / 99.9
- Stock P/E
- Book Value ₹ 53.3
- Dividend Yield 0.00 %
- ROCE -1.64 %
- ROE -1.71 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|
| 334 | 182 | 111 | |
| 299 | 190 | 131 | |
| Operating Profit | 35 | -8 | -20 |
| OPM % | 11% | -5% | -18% |
| 5 | 10 | 10 | |
| Interest | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 |
| Profit before tax | 38 | -1 | -12 |
| Tax % | 24% | -142% | |
| 29 | 0 | -10 | |
| EPS in Rs | 8.91 | 0.07 | -2.31 |
| Dividend Payout % | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -59% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -149% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|
| Equity Capital | 33 | 43 | 43 |
| Reserves | 68 | 193 | 188 |
| 60 | 77 | 116 | |
| 52 | 29 | 14 | |
| Total Liabilities | 213 | 343 | 361 |
| 48 | 50 | 49 | |
| CWIP | 1 | 43 | 113 |
| Investments | 34 | 38 | 4 |
| 130 | 212 | 195 | |
| Total Assets | 213 | 343 | 361 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| 56 | 2 | |
| -55 | -144 | |
| -1 | 152 | |
| Net Cash Flow | -0 | 10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | 97 | 92 |
| Inventory Days | 17 | 22 |
| Days Payable | 62 | 56 |
| Cash Conversion Cycle | 52 | 57 |
| Working Capital Days | 71 | 109 |
| ROCE % | -2% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 Nov - Newspaper Publication of Postal Ballot dated November 12, 2024.
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
19 Nov - Increase in authorized share capital and appointment of director.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Newspaper Publication of the Financial Results for the quarter ended September 30, 2024.
-
Statement Of Deviation For The Quarter Ended September 30, 2024
13 Nov - No deviation in IPO fund utilization for Q3 2024.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
13 Nov - Monitoring Agency Report confirms full utilization of IPO proceeds.
Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever